Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lite Strategy, Inc.LITS · Entity 7396 | Director | June 24, 2026 | June 25, 2026 |
| Oruka Therapeutics, Inc.ABIO · Entity 3781 | Director | January 30, 2024 | January 31, 2024 |
| RiceBran TechnologiesRIBT · Entity 95201 | Director | January 03, 2024 | January 11, 2024 |
| SYNLOGIC, INC.SYBX · Entity 7801 | Director | April 26, 2025 | April 29, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lite Strategy, Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
After 2026-06-24 transaction · row 1
1 source rowRow 1 · 2026-06-24 · Purchase · Acquired 25,000 · Balance 125,000 F1: The price reported is a weighted-average price. These shares were purchased in multiple transactions with prices ranging from $0.8363 to $0.88 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted-average price. These shares were purchased in multiple transactions with prices ranging from $0.8363 to $0.88 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4.
Oruka Therapeutics, Inc.
Report date January 30, 2024 · Filed January 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2034-01-30 | Direct | 6,000 |
Reported balance
After 2024-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-30 · Grant · Acquired 6,000 · Balance 6,000 F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.
RiceBran Technologies
Report date January 03, 2024 · Filed January 11, 2024
This filing explicitly reported no securities owned.
SYNLOGIC, INC.
Report date April 26, 2025 · Filed April 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2025-04-26 transaction · row 1
1 source rowRow 1 · 2025-04-26 · Grant · Acquired 15,000 · Balance 15,000 F1: Per the Amended and Restated Non-Employee Director Compensation Program, amended on April 26, 2025, and the 2015 Equity Incentive Award Plan, the Board of Directors of Synlogic, Inc. awarded each Non-Employee Director 15,000 shares of restricted stock. The shares were granted on April 26, 2025 and will fully vest on December 15, 2025, subject to the Reporting Person continuing to provide services to the Company as a Non-Employee Director, through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Per the Amended and Restated Non-Employee Director Compensation Program, amended on April 26, 2025, and the 2015 Equity Incentive Award Plan, the Board of Directors of Synlogic, Inc. awarded each Non-Employee Director 15,000 shares of restricted stock. The shares were granted on April 26, 2025 and will fully vest on December 15, 2025, subject to the Reporting Person continuing to provide services to the Company as a Non-Employee Director, through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 20:30 UTC | Lite Strategy, Inc. LITS · Entity 7396 | PurchaseCommon Stock | 25,000 | $0.86 | $21,387.50 |
DisclosureSEC source: 0001193125-26-282864 · ownership.xml · nonDerivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 F1 · price: The price reported is a weighted-average price. These shares were purchased in multiple transactions with prices ranging from $0.8363 to $0.88 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:00 UTC | Lite Strategy, Inc. LITS · Entity 7396 | PurchaseCommon Stock | 70,000 | $1.40 | $97,699.00 |
DisclosureSEC source: 0001193125-25-328666 · ownership.xml · nonDerivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The price reported is a weighted-average price. These shares were purchaased in multiple transactions with prices ranging from $1.38 to $1.43 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 21:00 UTC | Lite Strategy, Inc. LITS · Entity 7396 | PurchaseCommon Stock | 12,100 | $1.88 | $22,777.04 |
DisclosureSEC source: 0001193125-25-289712 · ownership.xml · nonDerivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported is a weighted-average price. These shares were purchaased in multiple transactions with prices ranging from $1.87 to $1.90 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 22:08 UTC | Lite Strategy, Inc. LITS · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $2.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-286427 · ownership.xml · derivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-11-14 F2 · price: Received as compensation for service on the Board. F1 · derivative.exercise_date: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:00 UTC | Lite Strategy, Inc. LITS · Entity 7396 | GrantCommon Stock | 10,000 | $2.54 | $25,430.00 |
DisclosureSEC source: 0001193125-25-228265 · ownership.xml · nonDerivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,900 F1 · price: The price reported is a weighted-average price. These shares were purchaased in multiple transactions with prices ranging from $2.51 to $2.58 per share. The reporting person undertakes to provide Lite Strategy, Inc., any security holders of Lite Strategy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4. Read SEC document |
| July 15, 2025 Filed Jul 18, 2025 01:36 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000929638-25-002636 · form4.xml · derivative · entry 2 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-07-15 F1 · security: Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025. Read SEC document |
| April 26, 2025 Filed Apr 29, 2025 20:43 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-060253 · ownership.xml · nonDerivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Per the Amended and Restated Non-Employee Director Compensation Program, amended on April 26, 2025, and the 2015 Equity Incentive Award Plan, the Board of Directors of Synlogic, Inc. awarded each Non-Employee Director 15,000 shares of restricted stock. The shares were granted on April 26, 2025 and will fully vest on December 15, 2025, subject to the Reporting Person continuing to provide services to the Company as a Non-Employee Director, through such vesting date. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:00 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantCommon Stock | 7,900 | $3.16 | $24,980.59 |
DisclosureSEC source: 0000950170-24-062362 · ownership.xml · nonDerivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,900 F1 · price: The price reported is a weighted-average price. These shares were purchaased in multiple transactions with prices ranging from $3.11 to $3.21 per share. The reporting person undertakes to provide MEI Pharma, Inc., any security holders of MEI Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set in this Form 4. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 21:09 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000950170-24-034866 · ownership.xml · derivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2034-03-19 F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:25 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-24-002479 · doc4.xml · derivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2034-01-30 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| December 18, 2023 Filed Dec 21, 2023 02:25 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0000950170-23-072035 · ownership.xml · derivative · entry 2 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-12-18 F2 · derivative.exercise_date: Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date. Read SEC document |
| December 18, 2023 Filed Dec 21, 2023 02:25 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Options (Right to Buy) · Derivative | 6,700 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0000950170-23-072035 · ownership.xml · derivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2033-12-18 F1 · derivative.exercise_date: Such option shall be vested and exercisable with respect to 12.5% of the shares on the date of grant and the remainder of the option will vest and become exercisable in equal monthly amounts of 12.5% of the shares subject to the option, beginning on the first day of each calendar month following the date of grant (January 1, 2024) and continuing through July 1, 2024 with full vesting on July 1, 2024, subject to continued service through the applicable vesting date. Read SEC document |
| December 18, 2023 Filed Jan 12, 2024 21:00 UTC Amendment | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.19 | $0.00 |
DisclosureSEC source: 0000950170-24-004228 · ownership.xml · derivative · entry 2 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-12-18 F2 · derivative.exercise_date: Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date. Read SEC document |
| December 18, 2023 Filed Jan 12, 2024 21:00 UTC Amendment | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 6,700 | $0.00 Strike: $6.19 | $0.00 |
DisclosureSEC source: 0000950170-24-004228 · ownership.xml · derivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2033-12-18 F1 · derivative.exercise_date: Such option shall be vested and exercisable with respect to 12.5% of the shares on the date of grant and the remainder of the option will vest and become exercisable in equal monthly amounts of 12.5% of the shares subject to the option, beginning on the first day of each calendar month following the date of grant (January 1, 2024) and continuing through July 1, 2024 with full vesting on July 1, 2024, subject to continued service through the applicable vesting date. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:19 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-061897 · doc4.xml · derivative · entry 1 Flynn James P · CIK 0001955965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-12-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 36 equal monthly installments beginning as of December 15, 2022. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.